Estimates suggest that >400,000 new cases of bladder cancer and 165,000 bladder-cancerrelated deaths occur worldwide each year 1 . Approximately 25% of cases are muscleinvasive bladder cancers (MIBCs), which comprise a heterogeneous group of tumours. For patients with metastatic disease, the prognosis is generally poor. Until the approval of immune-checkpoint inhibitors (ICIs) in 2016, no new drugs had been approved in more than two decades, and survival outcomes remained unchanged 2 . This dismal situation has driven efforts to unveil the molecular features of MIBC, both to fully understand the biology and molecular heterogeneity, and to guide disease management through the identification of prognostic and predictive biomarkers. In 2014, The Cancer Genome Atlas (TCGA) consortium presented an analysis of data from 131 MIBCs that included whole-exome, RNA and microRNA (miRNA) sequencing, DNA-methylation and protein-expression data 3 . Findings from this and other studies have confirmed that MIBC is not only clinically heterogeneous, but also has a high level of molecular diversity. Notable findings included a high somatic mutation rate, similar to that of non-small-cell lung cancer and melanoma, statistically significant mutations in 32 genes, and subclassification of MIBC into four subtypes based on mRNA expression, with distinct phenotypes and implications for survival 3 . Considerable mutational diversity was found: only TP53 was mutated in clusters. Strikingly, for one of them, consisting of tumours with high mutational burden, high APOBEC-associated mutational load and high predicted neoantigen load, the 5-year survival probability was extremely high (75%) compared with the cluster with the lowest mutational burden (22%). Hypothetically, this observation reflects a greater host antitumour immune response. The clinical implications of these features must now be further examined in clinical trials and will be of particular interest in terms of response to ICIs.
WES of these 412 tumours revealed 58 significantly mutated genes, 18 of which were mutated in >10% of samples. A very high frequency (89%) of alterations was reported in TP53, RB1 and genes involved in cell cycle regulation, with frequent alterations in chromatin modifiers and regulators, and a broad range of alterations affecting canonical signalling pathways, including mutations or copy-number gains in EGFR, FGFR3, HER2 or HER3. However, given the heterogeneity of MIBC, analysis of an even larger panel will be required to generate a complete catalogue of low-frequency mutations. In a tumour type with such a high background mutation frequency, >3,000 samples might be needed to reliably detect genes mutated in 2% of samples 6 . With reduced sequencing costs, this task can undoubtedly be achieved within the next few years, ideally using clinically annotated samples from patients participating in trials.
mRNA sequencing data revealed five disease subtypes (luminal-papillary, luminal-infiltrated, luminal, basal-squamous and neuronal), which align closely with the four expression subtypes identified in the 2014 study 3 (FIG. 1) .
Overall, basal and luminal features divide the tumours into two major groups, as described in the previous TCGA data set 3 and other studies. Luminal tumours were found to retain aspects of urothelial differentiation, including expression of uroplakin genes and transcription factors implicated in urothelial differentiation, whereas basal tumours express markers characteristic of the nonmalignant basal cells of the urothelium. A key subtype is luminalinfiltrated, characterized by markers suggesting the presence of stromal cells. This group aligns with the TCGA 2014 subtype II, reported to be sensitive to ICIs 7 and a 'p53-like' subtype, reported to be resistant to cisplatin-based chemotherapy 8 . Two additional subtypes >40% of samples, and the next most frequently mutated gene (KMT2D), in only 27%. A long 'tail' of infrequently mutated genes was identified, and many were not confirmed as significantly mutated. More samples are needed to develop a fully comprehensive mutational profile for such a diverse malignancy. Data from an expanded TCGA cohort of 412 tumours have now been published 4 , moving the field closer to a comprehensive catalogue of molecular features, and enabling the influence of molecular subtype on patient outcomes to be examined in greater detail. The data set includes data from whole-exome, mRNA, long non-coding RNA (lncRNA), and miRNA sequencing, DNA copy-number variation and methylation, and reversephase protein arrays 4 . The tumours analysed were chemotherapy naive and 86% were pure urothelial carcinomas. Some urothelial carcinomas with a variant histology were included, reflecting the range of phenotypes commonly found in this group, and providing a balanced view of the disease at diagnosis.
The large body of whole-exome sequencing (WES) data presented enabled a detailed analysis of mutational signatures. A high mutation rate was confirmed (mean 8.2 and median 5.8 nonsynonymous mutations per megabase) and five mutational signatures were identified. Two of them, both variants of the APOBEC signature 5 , accounted for 67% of all singlenucleotide variants. Unsupervised clustering analyses revealed four mutational signature (luminal and neuronal) were described. The latter, also described by others 9 , comprised ~5% of MIBCs analyzed and was associated with the worst clinical outcomes. The majority of neuronal MIBCs did not have histological features suggestive of a neuroendocrine origin; thus, the expression signature defined will enable future identification studies.
In addition to mRNA-based subtypes, hypermethylation and hypomethylation, lncRNA and miRNA clusters were derived. All overlap with the mRNA-based subtypes, and in particular the lncRNA and miRNA subtypes provide further subdivision. These smaller subsets now merit more detailed evaluation of their diagnostic and prognostic value.
Around 10-15% of patients with nonmuscle-invasive bladder cancer (NMIBC) are likely to progress to MIBC, although the specific molecular features driving such progression remain unclear. Of note, MIBCs with the highest levels of hypomethylation frequently had FGFR3 alterations and no TP53 or RB1 mutations, features prevalent among NMIBC. Other features of these MIBCs, from the luminal-papillary mRNA subtype, included low mutation burden, low levels of hypermethylation, high frequency of CDKN2A deletion and better overall survival than other hypomethylation subtypes. Further mining of this data set might enable definition of robust prognostic signatures for the identification of noninvasive tumours, particularly stage T1 tumours that confer a high risk of disease progression and merit early radical surgery.
These findings 4 have many therapeutic implications: patients with luminal-papillary tumours might benefit from treatment with FGFR inhibitors, and those with luminalinfiltrated tumours from ICIs but not cisplatinbased chemotherapy. These observations provide predictive hypotheses that can now be tested by retrospective analyses, and in novel biomarker-driven trials. Given the biological heterogeneity of MIBC, a considerable challenge of the application of the current knowledge in the clinic exists. High-quality evidence demonstrating the clinical benefits of the therapeutic hypotheses generated by this and other molecular analyses is needed. Evidence has been presented already indicating superior responses of tumours of the basal subtype 10 , and of the relative resistance of other subtypes 8 to neoadjuvant chemotherapy. A fine-grained understanding of sensitivity to chemotherapy, targeted therapy and immune-based therapeutics is now required. To achieve this task, the development of subtype classification signatures measurable with panels of a limited number of mRNA and/or immunohistochemical markers, robust funding for the routine clinical use of molecular profiling, and close collaboration between scientists and clinicians will be essential.
